Sort By:
Featured

RSV Vaccine

This study will evaluate the safety and effectiveness of an RSV vaccine in women between the ages of 18-45 to increase antibodies to RSV infection. The study will last approximately 6 months with 4 visits to our office and 1 telephone call. Compensation is available for time and travel up to $600, for those who qualify.

View Trial Details
Ages 18 - 45
Gender For female patients only
Compensation* $600
Study Topics Vaccine

*Compensation for time and travel may be available to those who qualify.